---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-006688"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T05:11:29.565628+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens

## Summary
- Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)
- Q4 Afrezza net revenue $11.3M (+13% vs Q4 2020); collaborations revenue $1.2M
- Cash and investments $260.7M at Dec 31, 2021 vs $67.2M a year ago; includes $230M convertible note and ~$100M sale-leaseback
- Full-year net loss $80.9M ($0.32/sh) vs $57.2M ($0.26/sh) in 2020; non-GAAP loss $61.7M ($0.25/sh)
- Tyvaso DPI PDUFA deadline extended to May 2022; clofazimine Phase 1 trial commenced in 1Q 2022

## SEC filing metadata
- accession: 0001564590-22-006688
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/0001564590-22-006688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/mnkd-8k_20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-006688
- JSON: https://secwatch.observer/filing/0001564590-22-006688.json
- Plain text: https://secwatch.observer/filing/0001564590-22-006688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.